clinical trial · NCT02649959
An Open Label Study of CM-AT for the Treatment of Children With Autism
Curemark·phase3·active not recruiting·n = 405
AutismCM-AT
brief summary
This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.
started
Oct 1, 2015
primary completion
Jan 1, 2028
completion
Jan 1, 2028
last updated
Mar 18, 2026
detailed description
Autism is clearly a significant cause of disability in the pediatric population. Treatment is based on the observation that many children with autism do not digest protein. CM-AT is a proprietary enzyme that is designed as a granulated powder taken three times daily.
official title
An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol